Jan Mossemann

Jan Mossemann

Auto-generated profile, based on publicly available information

Jan Mossemann

Cell Biology Program, Hospital for Sick Children, Toronto, Canada

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2026 in Science Advances
Verified
Journal Article
Closed access
JMJan Mossemann
Jan Mossemann
BMBrunna X. Martins
Brunna X. Martins
YZYixuan Zhao
Yixuan Zhao
FAFiorelle Aguilar
Fiorelle Aguilar
DTDaria Taskina
Daria Taskina
BSBlayne A. Sayed
Blayne A. Sayed
Lytic cell death pathways drive hepatic ischemia-reperfusion injury (IRI). The transmembrane protein ninjurin-1 (NINJ1) aggregates in the plasma membrane to permeabilize the cell during multiple cell death pathways implicated in hepatic IRI. We hypothesized that NINJ1 mediates liver IRI and that its inhibition would mitigate injury. We found that NINJ1 is highly expressed in human liver tissue and that its up-regulation and activation correlate with early allograft dysfunction in liver transplant patients. Using a segmental hepatic IRI model in mice and rats, Ninj1 genetic deletion or pharmacologic inhibition diminished acute injury. Mice with hepatocyte- or macrophage-specific Ninj1 knockout had reduced hepatocellular injury following IRI, suggesting that NINJ1 within both populations contributes to the resulting liver injury. Mechanistically, we found that hepatocytes and Kupffer cells are susceptible to hypoxia-induced NINJ1-mediated plasma membrane rupture, which can be pharmacologically prevented. We therefore position NINJ1 as a potential new therapeutic target to limit hepatic IRI, with important implications for liver transplantation.